Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice

Cancer Research

Volumn 68, Issue 21, 2008, Pages 8661-8666

  Lee, Cathy ^a   Dhillon, Jaspreet ^a   Wang, Michelle Y C ^b   Gao, Yuanyuan ^a   Hu, Kaiji ^a   Park, Eugene ^a   Astanehe, Arezoo ^a   Hung, Mien Chie ^c,d   Eirew, Peter ^b   Eaves, Connie J ^b   Dunn, Sandra E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SMALL INTERFERING RNA; STAT3 PROTEIN; Y BOX BINDING PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT GENE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING;

EID: 55349110263     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1082     Document Type: Article

References (20)

1. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
2. Wu J, Stratford AL, Astanehe A, Dunn SE. YB-1 is a transcription/ translation factor that orchestrates the oncogenome by hardwiring signal transduction to gene expression. Translat Oncogen 2007;2:1-17.
3. Fujii T, Kawahara A, Basaki Y, et al. Expression of Her-2 and estrogen receptor a depends upon nuclear localization of Y-box binding protein-1 in human breast cancers. Cancer Res 2008;68:1504-12.
4. Sutherland BW, Kucab JE, Wu J, et al. Akt phosphorylates the Y-box binding protein-1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 2005;24:4281-92.
5. Bergmann S, Royer-Pokora B, Fietze E, et al. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res 2005;10:4078-87.
6. Wu J, Lee C, Yokom D, et al. Disruption of the Y-box binding protein-1 (YB-1) results in suppression of the epidermal growth factor receptor and Her-2. Cancer Res 2006;66:4872-9.
7. To K, Zhao Y, Jiang H, et al. The phosphoinositide-dependent kinase-1 inhibitor, 2-amino-n-[4-5-(2-phenanthrenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl] -acetaminde (OSU03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor. Mol Pharmocol 2007;72 no 3:641-52.
8. Liu H, Ma Y, Cole SM, et al. Serine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival. Blood 2003;102:344-52.
9. Stratford AL, Habibi G, Astanehe A, et al. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer providing a potential target for therapy. Breast Cancer Res 2007;9:1-14.
10. Konnikova L, Kotecki M, Kruger MW, Cochran BH. Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer 2003;3:1-9.
11. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 is an Oncogene. Cell 1999;98:295-303.
12. Gritsko T, Williams A, Turkson J, et al. Persistant activation of Stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 2006;12:11-9.
13. Yeh YT, Ou-Yang F, Chen IF, et al. STAT3 ser727 phosphorylation and its association with negative estrogen receptor status in breast infiltrating ductal carcinoma. Int J Cancer 2006;118:2943-7.
14. Fernandes A, Hamburger AW, Gerwin BI. ErbB-2 kinase is required for constitutive Stat3 activation in malignant human lung epithelial cells. Int J Cancer 1999;83:564-70.
15. Garcia R, yu C, Hudnall A, et al. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Diff 1997;8:1267-76.
16. Yokogami K, Wakisaka S, Avruch J, Reeves SA. Serine phosphorylation and maximal activation of STAT3 during CNTFsignaling is mediated by the rapamycin target mTOR. Curr Biol 2000;10:47-50.
17. Wen Z, Zhong Z, Darnell JEJ. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995;82:241-50.
18. Androutsellis-Theotokis A, Leker RR, Soldner F, et al. Notch signaling regulates stem cell number in vitro and in vivo. Nature 2006;442:823-6.
19. Berishaj M, Gao SP, Ahmed S, et al. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res 2007;9:R32.
20. Zhou JR, Wulfkhuhle JD, Zhang HT, et al. Activation of the PTEN/mTOR/Stat3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Nat Acad Sci U S A 2007;104:16158-63.